Insulin pump therapy with automated insulin suspension in response to hypoglycemia: Reduction in nocturnal hypoglycemia in those at greatest risk
Authors: Choudhary, P., Shin, J., Wang, Y., Evans, M.L., Hammond, P.J., Kerr, D., Shaw, J.A.M., Pickup, J.C. and Amiel, S.A.
Journal: Diabetes Care
Volume: 34
Issue: 9
Pages: 2023-2025
eISSN: 1935-5548
ISSN: 0149-5992
DOI: 10.2337/dc10-2411
Abstract:OBJECTIVE - To evaluate a sensor-augmented insulin pump with a low glucose suspend (LGS) feature that automatically suspends basal insulin delivery for up to 2 h in response to sensor-detected hypoglycemia. RESEARCH DESIGN AND METHODS - The LGS feature of the Paradigm Veo insulin pump (Medtronic, Inc., Northridge, CA) was tested for 3 weeks in 31 adults with type 1 diabetes. RESULTS - There were 166 episodes of LGS: 66% of daytime LGS episodes were terminated within 10 min, and 20 episodes lasted the maximum 2 h. LGS use was associated with reduced nocturnal duration ≤2.2 mmol/L in those in the highest quartile of nocturnal hypoglycemia at baseline (median 46.2 vs. 1.8min/day, P = 0.02 [LGS-OFF vs. LGS-ON]).Median sensor glucose was 3.9 mmol/L after 2-h LGS and 8.2 mmol/L at 2 h after basal restart. CONCLUSIONS - Use of an insulin pump with LGS was associated with reduced nocturnal hypoglycemia in those at greatest risk and was well accepted by patients. © 2011 by the American Diabetes Association.
Source: Scopus
Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk.
Authors: Choudhary, P., Shin, J., Wang, Y., Evans, M.L., Hammond, P.J., Kerr, D., Shaw, J.A.M., Pickup, J.C. and Amiel, S.A.
Journal: Diabetes Care
Volume: 34
Issue: 9
Pages: 2023-2025
eISSN: 1935-5548
DOI: 10.2337/dc10-2411
Abstract:OBJECTIVE: To evaluate a sensor-augmented insulin pump with a low glucose suspend (LGS) feature that automatically suspends basal insulin delivery for up to 2 h in response to sensor-detected hypoglycemia. RESEARCH DESIGN AND METHODS: The LGS feature of the Paradigm Veo insulin pump (Medtronic, Inc., Northridge, CA) was tested for 3 weeks in 31 adults with type 1 diabetes. RESULTS: There were 166 episodes of LGS: 66% of daytime LGS episodes were terminated within 10 min, and 20 episodes lasted the maximum 2 h. LGS use was associated with reduced nocturnal duration ≤2.2 mmol/L in those in the highest quartile of nocturnal hypoglycemia at baseline (median 46.2 vs. 1.8 min/day, P = 0.02 [LGS-OFF vs. LGS-ON]). Median sensor glucose was 3.9 mmol/L after 2-h LGS and 8.2 mmol/L at 2 h after basal restart. CONCLUSIONS: Use of an insulin pump with LGS was associated with reduced nocturnal hypoglycemia in those at greatest risk and was well accepted by patients.
Source: PubMed
Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia Reduction in nocturnal hypoglycemia in those at greatest risk
Authors: Choudhary, P., Shin, J., Wang, Y., Evans, M.L., Hammond, P.J., Kerr, D., Shaw, J.A.M., Pickup, J.C. and Amiel, S.A.
Journal: DIABETES CARE
Volume: 34
Issue: 9
Pages: 2023-2025
ISSN: 0149-5992
DOI: 10.2337/dc10-2411
Source: Web of Science (Lite)
Preferred by: David Kerr
Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk.
Authors: Choudhary, P., Shin, J., Wang, Y., Evans, M.L., Hammond, P.J., Kerr, D., Shaw, J.A.M., Pickup, J.C. and Amiel, S.A.
Journal: Diabetes care
Volume: 34
Issue: 9
Pages: 2023-2025
eISSN: 1935-5548
ISSN: 0149-5992
DOI: 10.2337/dc10-2411
Abstract:Objective
To evaluate a sensor-augmented insulin pump with a low glucose suspend (LGS) feature that automatically suspends basal insulin delivery for up to 2 h in response to sensor-detected hypoglycemia.Research design and methods
The LGS feature of the Paradigm Veo insulin pump (Medtronic, Inc., Northridge, CA) was tested for 3 weeks in 31 adults with type 1 diabetes.Results
There were 166 episodes of LGS: 66% of daytime LGS episodes were terminated within 10 min, and 20 episodes lasted the maximum 2 h. LGS use was associated with reduced nocturnal duration ≤2.2 mmol/L in those in the highest quartile of nocturnal hypoglycemia at baseline (median 46.2 vs. 1.8 min/day, P = 0.02 [LGS-OFF vs. LGS-ON]). Median sensor glucose was 3.9 mmol/L after 2-h LGS and 8.2 mmol/L at 2 h after basal restart.Conclusions
Use of an insulin pump with LGS was associated with reduced nocturnal hypoglycemia in those at greatest risk and was well accepted by patients.Source: Europe PubMed Central